Short Communication: Management of patients with extensive-stage small-cell lung cancer treated with radiotherapy: A survey of practice

Kate Haslett, Dirk de Ruysscher, Rafal Dziadziuszko, Matthias Guckenberger, Cecile Le Pechoux, Ursula Nestle, Ben Slotman, Corinne Faivre-Finn

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objectives: The results of the randomized phase 3 CREST trial evaluating the use of thoracic radiotherapy for extensive-stage small-cell lung cancer (ES-SCLC) were published in the Lancet in 2015. The primary endpoint (10% overall survival difference at 1-year) was not achieved, but there was significant improvement in 2-year overall survival (13% vs 3%; p = 0.004) and low toxicity rates, suggesting thoracic radiotherapy should be considered for ES-SCLC patients who respond to chemotherapy. Questions have been raised as to whether these results will lead to a change in practice. Materials and methods: We developed an electronic survey to determine the impact of the publication on clinical practice across some European countries. Results and conclusion: We report the results of our survey, which suggest the CREST trial has changed practice, resulting in an increase in the use of thoracic radiotherapy amongst the surveyed centers from 25% to 85%. Furthermore the dose and fractionation schedule used in the trial has been widely adopted across Europe.
Original languageEnglish
Pages (from-to)18-22
JournalCancer Treatment and Research Communications
Volume17
DOIs
Publication statusPublished - 2018

Cite this